Status:

COMPLETED

Study of AS1411 in Advanced Solid Tumours

Lead Sponsor:

Antisoma Research

Conditions:

Advanced Solid Tumors

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

A Phase I open label study of AS1411 in advanced solid tumours. Objectives include determining the MTD and DLT of AS1411, to determine the PK profile of AS1411 and to obtain preliminary evidence of cl...

Eligibility Criteria

Inclusion

  • Patients with advanced solid tumours that were refractory to conventional/standard treatment
  • Age \>/ 18 years
  • ECOG performance status \</ 2 (Karnofsky \>/60%
  • Life expectancy \>/ 8 weeks
  • Adequate organ and marrow function

Exclusion

  • Radiotherapy or chemotherapy in the 4 weeks before study entry (6 weeks for nitrosourea or mitomycin C
  • Lack of recovery from adverse events (AEs) caused by agents administered before study entry; current use of other investigational agent(s)
  • Uncontrolled brain metastases including a need for corticosteroid therapy
  • Pregnancy
  • Uncontrolled intercurrent illness
  • Psychiatric illness/social situations that could limit compliance

Key Trial Info

Start Date :

September 1 2003

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

February 1 2007

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT00881244

Start Date

September 1 2003

End Date

February 1 2007

Last Update

April 15 2009

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

James Graham Brown Cancer Center, University of Louisville

Louisville, Kentucky, United States, 40202